Short Interest Watching: What Will Happen to Supernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Next? The Stock Has Decline in Shorts

November 17, 2016 - By Nellie Frank   ·   0 Comments

Short Interest Watching: What Will Happen to Supernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Next? The Stock Has Decline in Shorts

The stock of Supernus Pharmaceuticals Incorporated (NASDAQ:SUPN) registered a decrease of 1.49% in short interest. SUPN’s total short interest was 2.33 million shares in November as published by FINRA. Its down 1.49% from 2.37M shares, reported previously. With 572,900 shares average volume, it will take short sellers 4 days to cover their SUPN’s short positions. The short interest to Supernus Pharmaceuticals Incorporated’s float is 5.15%. The stock decreased 1.56% or $0.38 during the last trading session, hitting $23.62. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 44.79% since April 15, 2016 and is uptrending. It has outperformed by 40.17% the S&P500.

Supernus Pharmaceuticals, Inc. is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system diseases. The company has a market cap of $1.17 billion. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It has a 46.32 P/E ratio. It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD).

Insitutional Activity: The institutional sentiment increased to 1.26 in Q2 2016. Its up 0.11, from 1.15 in 2016Q1. The ratio improved, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
The New York-based Mutual Of America Cap Management Ltd has invested 0.24% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). State Common Retirement Fund accumulated 0.01% or 269,600 shares. Moreover, California State Teachers Retirement Systems has 0% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 98,380 shares. Proshare Advsr Limited Liability Corporation holds 0.01% or 43,300 shares in its portfolio. Ranger Invest L P has invested 2.91% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Cap Mngmt Corporation Va last reported 35,630 shares in the company. D E Shaw Com Inc, a New York-based fund reported 15,473 shares. Moreover, Piermont Cap Management Inc has 0.36% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 67,881 shares. Panagora Asset Mgmt Inc last reported 0.03% of its portfolio in the stock. Iguana Healthcare Mngmt owns 225,000 shares or 1.86% of their US portfolio. State Street Corp accumulated 1.15 million shares or 0% of the stock. Sei last reported 0.02% of its portfolio in the stock. Products Partners Ltd Llc has 0.16% invested in the company for 97,600 shares. Legal General Gru Public Limited Company accumulated 7,282 shares or 0% of the stock. Pitcairn has 0.03% invested in the company for 11,927 shares.

Insider Transactions: Since September 16, 2016, the stock had 0 insider purchases, and 1 sale for $50,000 net activity. 2,000 Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares with value of $50,000 were sold by PATRICK GREGORY S.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage

Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. $28 is the highest target while $27 is the lowest. The $27.50 average target is 16.43% above today’s ($23.62) stock price. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) earned “Outperform” rating by Northland Capital on Wednesday, October 28. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Buy” rating given on Thursday, August 4 by Jefferies. The rating was downgraded by Piper Jaffray on Monday, July 18 to “Neutral”. The firm has “Market Perform” rating by Northland Capital given on Monday, July 18. As per Thursday, November 5, the company rating was maintained by Northland Capital. The firm has “Hold” rating by Zacks given on Wednesday, August 26.

SUPN Company Profile

Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Another recent and important Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news was published by Investorplace.com which published an article titled: “Supernus Pharmaceuticals Inc (SUPN) Stock Dips Despite Positive ADHD Data” on October 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>